GNRH1 and neoplasm: In parallel, the response of the patient donor of MDA PCa 183 to a gonadotropin-releasing hormone (GnRH) antagonist (Fig. 1A) was reflected by a drop in PSA blood levels (Fig. 1B) similar to the findings in MDA PCa 183 after castration, accompanied by improvement of symptoms associated with tumor burden.